Published in Cancer Weekly, February 19th, 1996
Results of this research were presented at the "Management of Advanced Cancer: Patient Needs, Challenges and New Treatment Options" symposium held in Prague, Czech Republic.
"Taxotere has the highest overall response rate reported to date - 56 percent - as a single agent in the treatment of late-stage breast cancer resistant to or that progresses during chemotherapy that includes anthracyclines, one of the most commonly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.